Prothena Corporation plc (PRTA) Jumps 6.76% on February 17

Equities Staff |

Prothena Corporation plc (PRTA) was among the biggest gainers on the Russell 2000 for Wednesday February 17 as the stock popped 6.76% to $34.12, representing a gain of $2.16 per share. Some 442,581 shares traded hands on 4,262 trades, compared with an average daily volume of 470,366 shares out of a total float of 31.52 million. The stock opened at $32.29 and traded with an intraday range of $34.95 to $31.53.

After today's gains, Prothena Corporation plc reached a market cap of $1.08 billion. Prothena Corporation plc has had a trading range between $76.42 and $22.84 over the last year, and it had a 50-day SMA of $52.55 and a 200-day SMA of $52.82.

Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.

Prothena Corporation plc is based out of Dublin, and has some 46 employees. Its CEO is Dale Schenk.

For a complete fundamental analysis analysis of Prothena Corporation plc, check out Equities.com’s Stock Valuation Analysis report for PRTA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

Snapchat

Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…

Spotify

Spotify is a online music service offering providing digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record…